Evaluation of effects of autologous peripheral blood stem cell transplantation on the response rates and survival rates in the patients with refractory or relapsed Hodgkin lymphoma and grey zone lymphoma
10.3760/cma.j.issn.1009-9921.2013.06.012
- VernacularTitle:自体造血干细胞移植治疗难治复发霍奇金淋巴瘤、灰区淋巴瘤的疗效及预后分析
- Author:
Jiahua NIU
;
Chun WANG
;
Shike YAN
;
Liping WAN
;
Jieling JIANG
;
Jun YANG
;
Yu CAI
- Publication Type:Journal Article
- Keywords:
Hodgkin disease;
Peripheral blood stem cell transplantation,autologous;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2013;22(6):357-361
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the response rate and survival rates of refractory or relapsed Hodgkin lymphoma (HL) and grey zone lymphoma patients treated with autologous peripheral blood stem cell transplantation (APBSCT).Methods From January 2004 to August 2012,30 HL and grey zone lymphoma patients were retrospectively analyzed.Statistical analysis was done to explore the long term outcome and prognostic factors of patients treated with APBSCT.Among all patients,the median age at transplantion was 30 (13-55) years old.Patients were major with nodular sclerosis HL and in stage Ⅲ/Ⅳ.Results Every patient had a successful collection.The median MNC cell dose infused was 6.8×108/kg [range (1.0-13.8)×108/kg] and median CD34+ cell dose infused was 6.3×106/kg [range (0.6-20.6)×106/kg].Median time to neutrophil engraftment was 9 days (range 8-12 days).28 patients were evaluable after transplantation with a median follow-up of 18.5 months (range 2.5-95.0 months).The overall response rate was 89.3 ％ [CR 64.3 ％ (18/28),PR 25.0 ％ (7/28)].The overall survival (OS) rate and progression free survival (PFS) rate at 5 year would be 78 ％ and 58 ％ for all patients.3 in 7 patients with no remission after salvage chemotherapy with rituximab plus chemotherapy before APBSCT got CR and 2 got PR.Univariate analysis showed that disease status and the number of replacement types of chemotherapy prior to transplantation affected OS,the history of radiotherapy prior to transplantation affected PFS.Conclusion APBSCT can increase CR rate,prolong survival time in patients with refractory or relapsed HL and grey zone lymphoma.Rituximab plus chemotherapy as a salvage therapy could raise CR rate before APBSCT.Chemosensitivity before transplantation affect outcome with APBSCT.Changing many types of chemotherapy is adverse for APBSCT.Salvage radiotherapy before APBSCT is not recommended.
